Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients

Table 6 Multiple regression analyses accounting for factors that affect total pill burden and pill burden from PBs

		Model 1		Model 2
		Total pill burden (pills/day/patient)	Pill burden from PBs (pills/day/patient)	Total pill burden (pills/day/patient)	Pill burden from PBs (pills/day/patient)
Gender (male)	β (P)		0.097 0.040
Age (years)	β (P)	- 0.110 0.011	- 0.250 < 0.001	- 0.090 0.037	- 0.255 < 0.001
Dialysis vintage (years)	β (P)	0.290 < 0.001	0.175 < 0.001	0.220 < 0.001	0.145 0.003
DM (yes)	β (P)	0.135 0.003		0.141 0.001
Serum P (mg/dL)	β (P)	0.210 < 0.001	0.144 0.003	0.196 < 0.001	0.140 0.004
Oral calcimimetics (user)	β (P)			0.175 <0.001	0.106 0.032
IV calcimimetics (user)	β (P)			0.094 0.034

Independent variables in model 1; gender (male), age (years), dialysis vintage (years), DM (yes), serum corrected Ca (mg/dL), serum P (mg/dL), serum i-PTH (pg/mL), serum Alb (g/dL), and nPCR (g/kg/day). Independent variables in model 2; model 1 + oral calcimimetics (user), IV calcimimetics (user), oral VDRAs (user), and IV VDRAs (user)

ISSN: 2059-1381